Vertex Pharmaceuticals | VRTX
Stock Price
451.02
Daily Change
0.87 0.19%
Monthly
-4.08%
Yearly
27.75%
Q4 Forecast
487.05


Peers Price Chg Day Year Date
AbbVie 177.16 5.32 3.10% 27.76% Nov/22
Acadia Pharmaceuticals 16.37 0.19 1.17% -26.56% Nov/22
Agios Pharmaceuticals 55.68 0.14 0.25% 149.35% Nov/22
Alnylam Pharmaceuticals 244.89 -1.91 -0.77% 50.31% Nov/22
Amgen 294.64 4.72 1.63% 10.99% Nov/22
Arrowhead Research 18.54 0.26 1.42% -36.33% Nov/22
Biogen 157.88 -0.16 -0.10% -31.93% Nov/22
BioMarin Pharmaceutical 64.26 0.81 1.28% -27.13% Nov/22
Bristol-Myers Squibb 58.86 0.66 1.13% 18.29% Nov/22
Gilead Sciences 90.01 0.40 0.45% 19.41% Nov/22
Incyte 71.72 1.33 1.89% 33.46% Nov/22
Insmed 73.15 -0.66 -0.89% 204.41% Nov/22
Ionis Pharmaceuticals 34.01 0.07 0.21% -31.75% Nov/22
J&J 155.20 -0.32 -0.21% 1.77% Nov/22
Merck 99.27 -0.86 -0.86% -2.55% Nov/22
Moderna 41.14 2.82 7.35% -47.61% Nov/22
Neurocrine Biosciences 125.65 0.65 0.52% 12.02% Nov/22
Novartis 93.68 2.12 2.32% 8.61% Nov/22
Pfizer 25.66 0.56 2.23% -15.87% Nov/22
PTC Therapeutics 43.23 0.34 0.79% 99.49% Nov/22
Ultragenyx Pharmaceutical 47.24 1.22 2.65% 20.69% Nov/22
Regeneron Pharmaceuticals 738.00 -5.43 -0.73% -7.55% Nov/22
Roche Holding 254.30 3.20 1.27% 6.69% Nov/22
Sanofi 93.17 2.30 2.53% 8.04% Nov/22
Sarepta Therapeutics 114.23 3.73 3.38% 37.84% Nov/22
United Therapeutics 372.89 5.53 1.51% 61.33% Nov/22
Vertex Pharmaceuticals 451.02 0.87 0.19% 27.75% Nov/22

Indexes Price Day Year Date
US500 5969 20.64 0.35% 30.93% Nov/22
USND 19004 31.23 0.16% 33.35% Nov/22
US400 3342 54.93 1.67% 30.52% Nov/22
US100 20776 35.45 0.17% 30.00% Nov/22

Vertex Pharmaceuticals traded at $451.02 this Friday November 22nd, increasing $0.87 or 0.19 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 4.08 percent. Over the last 12 months, its price rose by 27.75 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 487.05 by the end of this quarter and at 469.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.